Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ION440

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: Methyl CpG Binding Protein 2 (MECP2) · developed by IONIS PHARMACEUTICALS

Phase 1/2 Most advanced trial
IONS Developer
1 Registered trials

What is ION440?

ION440 is an antisense oligonucleotide targeting MECP2 mRNA, administered by intrathecal injection. It is being studied in MECP2 Duplication Syndrome, a neurological disorder caused by duplication of the MECP2 gene.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
Methyl CpG Binding Protein 2 (MECP2)
Mechanism
Gene silencing: Methyl CpG Binding Protein 2 (MECP2)
Therapy area
Neurology
Developer
IONIS PHARMACEUTICALS (IONS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
57WA6KDT3H

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06430385 Phase 1/2 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome Recruiting IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

More from IONIS PHARMACEUTICALS

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind ION440

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.